Genomics Clinical Applications: Validity, Utility and Public Policy
Partnered with Inst. of Human Genetics at U of MN
Registration: 7:30 am - 8:00 am
Program: 8:00 am - 5:00 pm
The practice of medicine is being impacted by the rapid development of technologies to sequence the genome and the use of individual DNA sequence information to direct clinical care. Healthcare providers are faced with an array of genetic tests that have the potential to predict disease as well as variations in response to medications. Personalized medicine is directed at selecting the right drug, for the right patient, at the right dose to maximize effectiveness and minimize toxicities. But how are these decisions made, and how will they impact the healthcare system?
In this Symposium we will address how healthcare providers decide genetic testing validity and utility in clinical practice. Because the role of genetic counseling is expanding, especially with direct to consumer marketing, we will address how the population and clinical practitioners are being informed. The need for rapid, high-throughput diagnostic testing is being met with an emerging technology that assures a $200 full human genome is not far from reality. The current and rapidly changing technologies in genetic diagnostics will be discussed. With the new role of genomics in clinical decision-making we will address privacy and ethical considerations. National experts in each of these areas from large healthcare providers, the University of Minnesota, and the Mayo Clinic will provide their perspective on these issues. Finally, as the healthcare system is under increasing scrutiny by the federal government, Senator Al Franken will provide his perspective on the impact of government in developing public policies in personalized healthcare.
This one day Symposium will set the stage for continued community dialog in effectively incorporating the clinical application of genomics.
Please note, this program includes a luncheon.
Many thanks to our program sponsor: Agilent Technologies
Kenneth B. Beckman, PhD, Director, Biomedical Geonomics Center, University of Minnesota; Al Franken, United States Senator, Minnesota, United States Senate; Brian Dawson, Chair of the Division of Lab Genetics, Mayo Clinic; Betsy Hirsch, Director, Cytogenetics Laboratory, University of Minnesota; Jeffrey Kahn, PhD, MPH, Director, Center for Bioethics, University of Minnesota; Bonnie LeRoy, Director, Genetic Counseling Program, University of Minnesota; Lee Newcomer, MD, Sr. Vice President of Oncology, UnitedHealth Group; Brian Van Ness, PhD, Director of the Institute of Human Genetics, University of Minnesota
Kenneth B. Beckman, PhD is the Director, Biomedical Genomics Center and Associate Professor in the Department of Genetics, Cell Biology, and Developmental Biology. (more)
Al Franken is a U.S. Senator for Minnesota and member of the Federal Committee on Health & Education. (more)
Brian Dawson is the Chair the Division of Laboratory Genetics and Vice-Chair Business Development. (more)
Betsy Hirsch uses cytogenetic techniques to elucidate constitutional and acquired chromosome abnormalities. In clinically oriented studies, her laboratory (more)
Jeffrey Kahn, PhD, MPH is Director of the Center for Bioethics, and holds the Maas Family Endowed Chair in Bioethics. He is also Professor in the Department of Medicine, School of Medicine; and (more)
Bonnie LeRoy is the Director of Graduate Program in Genetic Counseling. Her primary focus is on fully preparing graduate students to enter the profession of genetic counseling. (more)
Lee Newcomer, MD - Bio coming soon.
Brian Van Ness, PhD 's lab research is directed at defining genetic deregulation that contributes to lymphoid malignancies, particularly multiple myeloma. (more)
The following topics will be addressed:
Marriott - Minneapolis West
9960 Wayzata Blvd.
Minneapolis, MN 55426
Directions / Map